155 related articles for article (PubMed ID: 19433989)
1. Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer.
Custodio AB; González-Larriba JL; Bobokova J; Calles A; Alvarez R; Cuadrado E; Manzano A; Díaz-Rubio E
J Thorac Oncol; 2009 Jul; 4(7):891-910. PubMed ID: 19433989
[TBL] [Abstract][Full Text] [Related]
2. Role of adjuvant chemotherapy in NSCLC (stages I to III).
Coleman MH; Bueno R
Surg Oncol Clin N Am; 2011 Oct; 20(4):757-67. PubMed ID: 21986270
[TBL] [Abstract][Full Text] [Related]
3. Individualized adjuvant chemotherapy for surgically resected lung cancer and the roles of biomarkers.
Ikeda N; Nagase S; Ohira T
Ann Thorac Cardiovasc Surg; 2009 Jun; 15(3):144-9. PubMed ID: 19597387
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant treatment of non-small-cell lung cancer: how do we improve the cure rates further?
Wozniak AJ; Gadgeel SM
Oncology (Williston Park); 2007 Feb; 21(2):163-71; discussion 171, 174, 179-82. PubMed ID: 17396481
[TBL] [Abstract][Full Text] [Related]
5. Heat shock protein 70 as a predictive marker for platinum-based adjuvant chemotherapy in patients with resected non-small cell lung cancer.
Park TS; Kim HR; Koh JS; Jang SH; Hwang YI; Yoon HI; Chung JH; Kim CH; Kim SS; Kim WS; Jo J; Lee JC; Choi CM
Lung Cancer; 2014 Nov; 86(2):262-7. PubMed ID: 25261232
[TBL] [Abstract][Full Text] [Related]
6. Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoise.
Azzoli CG; Park BJ; Pao W; Zakowski M; Kris MG
J Thorac Oncol; 2008 Jan; 3(1):84-93. PubMed ID: 18166846
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study).
Toffart AC; Timsit JF; Couraud S; Merle P; Moro-Sibilot D; Perol M; Mastroianni B; Souquet PJ; Girard N; Jeannin G; Romand P; Chatellain P; Vesin A; Brambilla C; Brambilla E
Lung Cancer; 2014 Feb; 83(2):182-8. PubMed ID: 24388706
[TBL] [Abstract][Full Text] [Related]
8. Prediction of clinical outcome in multiple lung cancer cohorts by integrative genomics: implications for chemotherapy selection.
Broët P; Camilleri-Broët S; Zhang S; Alifano M; Bangarusamy D; Battistella M; Wu Y; Tuefferd M; Régnard JF; Lim E; Tan P; Miller LD
Cancer Res; 2009 Feb; 69(3):1055-62. PubMed ID: 19176396
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy for surgically resected non-small cell lung cancer.
Heon S; Johnson BE
J Thorac Cardiovasc Surg; 2012 Sep; 144(3):S39-42. PubMed ID: 22502967
[TBL] [Abstract][Full Text] [Related]
10. Optimal adjuvant therapy for non-small cell lung cancer--how to handle stage I disease.
Wakelee H; Dubey S; Gandara D
Oncologist; 2007 Mar; 12(3):331-7. PubMed ID: 17405898
[TBL] [Abstract][Full Text] [Related]
11. Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials.
Mouillet G; Monnet E; Milleron B; Puyraveau M; Quoix E; David P; Ducoloné A; Molinier O; Zalcman G; Depierre A; Westeel V;
J Thorac Oncol; 2012 May; 7(5):841-9. PubMed ID: 22722786
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer.
Visbal AL; Leighl NB; Feld R; Shepherd FA
Chest; 2005 Oct; 128(4):2933-43. PubMed ID: 16236970
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
[TBL] [Abstract][Full Text] [Related]
14. The role of adjuvant chemotherapy in early-stage and locally advanced non-small cell lung cancer.
Shapiro M
Cleve Clin J Med; 2012 May; 79 Electronic Suppl 1():eS42-5. PubMed ID: 22614965
[TBL] [Abstract][Full Text] [Related]
15. The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.
Sève P; Reiman T; Dumontet C
Lung Cancer; 2010 Feb; 67(2):136-43. PubMed ID: 19828208
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
17. The rationale for adjuvant chemotherapy in stage I non-small cell lung cancer.
Horn L; Sandler AB; Putnam JB; Johnson DH
J Thorac Oncol; 2007 May; 2(5):377-83. PubMed ID: 17473651
[TBL] [Abstract][Full Text] [Related]
18. [Adjuvant chemotherapy for resectable non-small cell lung cancer (NSCLC)].
Nakajima E; Katou H
Kyobu Geka; 2008 Jan; 61(1):4-8. PubMed ID: 18186265
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy for non-small cell lung cancer.
Pinder-Schenck M; Bepler G
Minerva Chir; 2009 Dec; 64(6):611-28. PubMed ID: 20029358
[TBL] [Abstract][Full Text] [Related]
20. The coming of age of molecular tumor profiling.
Antonoff MB; D'Cunha J
Semin Thorac Cardiovasc Surg; 2011; 23(1):8-9. PubMed ID: 21807290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
